No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
1
Filings (14d)
Data as of 2026-07-02
2026-07-02
Lixte Biotechnology completed its merger with Nomad Transportable Power Systems on July 1, 2026, making Nomad a wholly-owned subsidiary. In the merger, Lixte issued about 2.99 million common shares and over 50,000 shares of new Series D preferred stock (convertible into common stock at $1 per share) to Nomad shareholders. Lixte will hold a special stockholder meeting on September 4, 2026, to vote on approving the conversion of those preferred shares and other matters.
Who are the top institutional investors holding LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)?
Major stakeholders currently include Scotia Capital INC. ($869.3K), Renaissance Technologies LLC ($285.5K), Federation des caisses Desjardins du Quebec ($198.0K). Based on the latest 13F filings, there are a total of 14 tracked investment funds and institutions maintaining positions in LIXT.
What is the overall institutional sentiment toward LIXT recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $720.7K, driven by 6 managers accumulating shares while 8 reduced their exposure.
Which institutions have been selling or reducing their LIXT positions?
In the latest period, 2 funds trimmed their holdings, and 6 managers completely exited their positions. The aggregate reported sell value was $1.1M.
Are there any notable investors adding LIXT to their portfolios?
Yes, buying activity remains notable. 2 institutions opened new positions in {ticker}, and 4 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.3M.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter